# Efficacy and Safety of RPH-104 Treatment in Patients With Recurrent Pericarditis

> **NCT05107934** · PHASE2,PHASE3 · SUSPENDED · sponsor: **R-Pharm Overseas, Inc.** · enrollment: 80 (estimated)

## Conditions studied

- Recurrent Pericarditis

## Interventions

- **BIOLOGICAL:** RPH-104
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05107934
- **Lead sponsor:** R-Pharm Overseas, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2025-12
- **Primary completion:** 2027-05
- **Final completion:** 2027-10
- **Target enrollment:** 80 (ESTIMATED)
- **Why stopped:** due to the decision of company Top management. No subjects were recruited, none of sites were initiated
- **Last updated:** 2024-11-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05107934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05107934, "Efficacy and Safety of RPH-104 Treatment in Patients With Recurrent Pericarditis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05107934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*